Report cover image

Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Dise

Publisher Transparency Market Research Pvt. Ltd.
Published May 26, 2022
Length 232 Pages
SKU # TNPR17326568

Description

Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Companies Mentioned

Baxalta Incorporated
Biotest AG
China Biologic Products, Inc.
CSL Behring LLC
Grifols S.A.
Kedrion S.p.A.
LFB Biomedicaments S.A.
Octapharma AG
Sanquin Plasma Products B.V."


Countries

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Forecast Year (first) - 2022

Forecast Year (last) - 2031

Forecast Year ( first)  Value - 11.2

Forecast Year (last) Value - 20.5

CAGR % - 0.073

Currency - US$ Bn

Table of Contents

232 Pages
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2. Market Share Analysis, by Region, 2017
3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map
4. Market Overview
4.1. Indication Overview
4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Rise in prevalence of autoimmune disorders
5.2.2. Increase in global geriatric population
5.2.3. Growing usage in off-label indications
5.2.4. Improved technology for production and purification methods
5.2.5. Favorable government initiatives and approvals
5.2.6. Increase in health care spending & improving health care infrastructure
5.2.7. Rise in incidence of hematological, neurological disorders
5.3. Restraints
5.3.1. High cost of treatment
5.3.2. Chronic side effects
5.3.3. Supply demand gaps
5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5. Opportunities
5.5.1. Application in newer indications
5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.6. Key Trends
5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031
5.8. Value Chain Analysis
5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook
6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1. Key Findings
6.2. Introduction
6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.4.2. Primary Humoral Immunodeficiency
6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)
6.4.4. Guillain-Barre Syndrome
6.4.5. Myasthenia Gravis
6.4.6. Multifocal Motor Neuropathy (MMN)
6.4.7. Kawasaki Disease
6.4.8. Hypogammaglobulinemia
6.4.9. Chronic Lymphocytic Leukemia
6.4.10. Others
6.5. Market Attractiveness Analysis, by Indication
6.6. Key Trends
7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Home Care
7.5. Market Attractiveness Analysis, by End-user
7.6. Key Trends
8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4. Market Attractiveness Analysis, by Region
9. North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1. Key Findings
9.2. Market Overview
9.3. Market Analysis, by Indication
9.3.1. Market Value Share Analysis, by Indication
9.3.2. Market Size (US$ Mn) Forecast, by Indication
9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.3.2.2. Primary Humoral Immunodeficiency
9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.3.2.4. Guillain-Barre Syndrome
9.3.2.5. Myasthenia Gravis
9.3.2.6. Multifocal Motor Neuropathy (MMN)
9.3.2.7. Kawasaki Disease
9.3.2.8. Hypogammaglobulinemia
9.3.2.9. Chronic Lymphocytic Leukemia
9.3.2.10. Others
9.4. Market Analysis, by End-user
9.4.1. Market Value Share Analysis, by End-user
9.4.2. Market Size (US$ Mn) Forecast, by End-user
9.4.2.1. Hospitals
9.4.2.2. Clinics
9.4.2.3. Home Care
9.5. Market Analysis, by Country
9.5.1. Market Value Share Analysis, by Country
9.5.2. Market Size (US$ Mn) Forecast, by Country, 2017–2031
9.5.2.1. U.S.
9.5.2.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Indication
9.6.2. By End-user
9.6.3. By Country
9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis
9.7.1. Market Size (US$ Mn) Forecast, by Indication
9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.7.1.2. Primary Humoral Immunodeficiency
9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.7.1.4. Guillain-Barre Syndrome
9.7.1.5. Myasthenia Gravis
9.7.1.6. Multifocal Motor Neuropathy (MMN)
9.7.1.7. Kawasaki Disease
9.7.1.8. Hypogammaglobulinemia
9.7.1.9. Chronic Lymphocytic Leukemia
9.7.1.10. Others
9.7.2. Market Size (US$ Mn) Forecast, by End-user
9.7.2.1. Hospitals
9.7.2.2. Clinics
9.7.2.3. Home Care Settings
9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis
9.8.1. Market Size (US$ Mn) Forecast, by Indication
9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.8.1.2. Primary Humoral Immunodeficiency
9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.8.1.4. Guillain-Barre Syndrome
9.8.1.5. Myasthenia Gravis
9.8.1.6. Multifocal Motor Neuropathy (MMN)
9.8.1.7. Kawasaki Disease
9.8.1.8. Hypogammaglobulinemia
9.8.1.9. Chronic Lymphocytic Leukemia
9.8.1.10. Others
9.8.2. Market Size (US$ Mn) Forecast, by End-user
9.8.2.1. Hospitals
9.8.2.2. Clinics
9.8.2.3. Home Care Settings
10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1. Key Findings
10.2. Market Overview
10.3. Market Analysis, by Indication
10.3.1. Market Value Share Analysis, by Indication
10.3.2. Market Size (US$ Mn) Forecast, by Indication
10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.3.2.2. Primary Humoral Immunodeficiency
10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.3.2.4. Guillain-Barre Syndrome
10.3.2.5. Myasthenia Gravis
10.3.2.6. Multifocal Motor Neuropathy (MMN)
10.3.2.7. Kawasaki Disease
10.3.2.8. Hypogammaglobulinemia
10.3.2.9. Chronic Lymphocytic Leukemia
10.3.2.10. Others
10.4. Market Analysis, by End-user
10.4.1. Market Value Share Analysis, by End-user
10.4.2. Market Size (US$ Mn) Forecast, by End-user
10.4.2.1. Hospitals
10.4.2.2. Clinics
10.4.2.3. Home Care
10.5. Market Analysis, by Country/Sub-region
10.5.1. Market Value Share Analysis, by Country/Sub-region
10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
10.5.2.1. U.K.
10.5.2.2. Germany
10.5.2.3. France
10.5.2.4. Spain
10.5.2.5. Italy
10.5.2.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By End-user
10.6.3. By Country/Sub-region
10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis
10.7.1. Market Size (US$ Mn) Forecast, by Indication
10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.7.1.2. Primary Humoral Immunodeficiency
10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.7.1.4. Guillain-Barre Syndrome
10.7.1.5. Myasthenia Gravis
10.7.1.6. Multifocal Motor Neuropathy (MMN)
10.7.1.7. Kawasaki Disease
10.7.1.8. Hypogammaglobulinemia
10.7.1.9. Chronic Lymphocytic Leukemia
10.7.1.10. Others
10.7.2. Market Size (US$ Mn) Forecast, by End-user
10.7.2.1. Hospitals
10.7.2.2. Clinics
10.7.2.3. Home Care Settings
10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis
10.8.1. Market Size (US$ Mn) Forecast, by Indication
10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.8.1.2. Primary Humoral Immunodeficiency
10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.8.1.4. Guillain-Barre Syndrome
10.8.1.5. Myasthenia Gravis
10.8.1.6. Multifocal Motor Neuropathy (MMN)
10.8.1.7. Kawasaki Disease
10.8.1.8. Hypogammaglobulinemia
10.8.1.9. Chronic Lymphocytic Leukemia
10.8.1.10. Others
10.8.2. Market Size (US$ Mn) Forecast, by End-user
10.8.2.1. Hospitals
10.8.2.2. Clinics
10.8.2.3. Home Care Settings
10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis
10.9.1. Market Size (US$ Mn) Forecast, by Indication
10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.9.1.2. Primary Humoral Immunodeficiency
10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.9.1.4. Guillain-Barre Syndrome
10.9.1.5. Myasthenia Gravis
10.9.1.6. Multifocal Motor Neuropathy (MMN)
10.9.1.7. Kawasaki Disease
10.9.1.8. Hypogammaglobulinemia
10.9.1.9. Chronic Lymphocytic Leukemia
10.9.1.10. Others
10.9.2. Market Size (US$ Mn) Forecast, by End-user
10.9.2.1. Hospitals
10.9.2.2. Clinics
10.9.2.3. Home Care Settings
10.10. Spain Intravenous Immunoglobulin (IVIG) Market Analysis
10.10.1. Market Size (US$ Mn) Forecast, by Indication
10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.10.1.2. Primary Humoral Immunodeficiency
10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.10.1.4. Guillain-Barre Syndrome
10.10.1.5. Myasthenia Gravis
10.10.1.6. Multifocal Motor Neuropathy (MMN)
10.10.1.7. Kawasaki Disease
10.10.1.8. Hypogammaglobulinemia
10.10.1.9. Chronic Lymphocytic Leukemia
10.10.1.10. Others
10.10.2. Market Size (US$ Mn) Forecast, by End-user
10.10.2.1. Hospitals
10.10.2.2. Clinics
10.10.2.3. Home Care Settings
10.11. Italy Intravenous Immunoglobulin (IVIG) Market Analysis
10.11.1. Market Size (US$ Mn) Forecast, by Indication
10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.11.1.2. Primary Humoral Immunodeficiency
10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.11.1.4. Guillain-Barre Syndrome
10.11.1.5. Myasthenia Gravis
10.11.1.6. Multifocal Motor Neuropathy (MMN)
10.11.1.7. Kawasaki Disease
10.11.1.8. Hypogammaglobulinemia
10.11.1.9. Chronic Lymphocytic Leukemia
10.11.1.10. Others
10.11.2. Market Size (US$ Mn) Forecast, by End-user
10.11.2.1. Hospitals
10.11.2.2. Clinics
10.11.2.3. Home Care Settings
10.12. Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.12.1. Market Size (US$ Mn) Forecast, by Indication
10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.12.1.2. Primary Humoral Immunodeficiency
10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.12.1.4. Guillain-Barre Syndrome
10.12.1.5. Myasthenia Gravis
10.12.1.6. Multifocal Motor Neuropathy (MMN)
10.12.1.7. Kawasaki Disease
10.12.1.8. Hypogammaglobulinemia
10.12.1.9. Chronic Lymphocytic Leukemia
10.12.1.10. Others
10.12.2. Market Size (US$ Mn) Forecast, by End-user
10.12.2.1. Hospitals
10.12.2.2. Clinics
10.12.2.3. Home Care Settings
11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Market Analysis, by Indication
11.3.1. Market Value Share Analysis, by Indication
11.3.2. Market Size (US$ Mn) Forecast, by Indication
11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.2.2. Primary Humoral Immunodeficiency
11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.3.2.4. Guillain-Barre Syndrome
11.3.2.5. Myasthenia Gravis
11.3.2.6. Multifocal Motor Neuropathy (MMN)
11.3.2.7. Kawasaki Disease
11.3.2.8. Hypogammaglobulinemia
11.3.2.9. Chronic Lymphocytic Leukemia
11.3.2.10. Others
11.4. Market Analysis, by End-user
11.4.1. Market Value Share Analysis, by End-user
11.4.2. Market Size (US$ Mn) Forecast, by End-user
11.4.2.1. Hospitals
11.4.2.2. Clinics
11.4.2.3. Home Care
11.5. Market Analysis, by Country/Sub-region
11.5.1. Market Value Share Analysis, by Country/Sub-region
11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.5.2.1. China
11.5.2.2. Japan
11.5.2.3. Australia
11.5.2.4. India
11.5.2.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By End-user
11.6.3. By Country/Sub-region
11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis
11.7.1. Market Size (US$ Mn) Forecast, by Indication
11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.7.1.2. Primary Humoral Immunodeficiency
11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.7.1.4. Guillain-Barre Syndrome
11.7.1.5. Myasthenia Gravis
11.7.1.6. Multifocal Motor Neuropathy (MMN)
11.7.1.7. Kawasaki Disease
11.7.1.8. Hypogammaglobulinemia
11.7.1.9. Chronic Lymphocytic Leukemia
11.7.1.10. Others
11.7.2. Market Size (US$ Mn) Forecast, by End-user
11.7.2.1. Hospitals
11.7.2.2. Clinics
11.7.2.3. Home Care Settings
11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis
11.8.1. Market Size (US$ Mn) Forecast, by Indication
11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.8.1.2. Primary Humoral Immunodeficiency
11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.8.1.4. Guillain-Barre Syndrome
11.8.1.5. Myasthenia Gravis
11.8.1.6. Multifocal Motor Neuropathy (MMN)
11.8.1.7. Kawasaki Disease
11.8.1.8. Hypogammaglobulinemia
11.8.1.9. Chronic Lymphocytic Leukemia
11.8.1.10. Others
11.8.2. Market Size (US$ Mn) Forecast, by End-user
11.8.2.1. Hospitals
11.8.2.2. Clinics
11.8.2.3. Home Care Settings
11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis
11.9.1. Market Size (US$ Mn) Forecast, by Indication
11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.9.1.2. Primary Humoral Immunodeficiency
11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.9.1.4. Guillain-Barre Syndrome
11.9.1.5. Myasthenia Gravis
11.9.1.6. Multifocal Motor Neuropathy (MMN)
11.9.1.7. Kawasaki Disease
11.9.1.8. Hypogammaglobulinemia
11.9.1.9. Chronic Lymphocytic Leukemia
11.9.1.10. Others
11.9.2. Market Size (US$ Mn) Forecast, by End-user
11.9.2.1. Hospitals
11.9.2.2. Clinics
11.9.2.3. Home Care Settings
11.10. India Intravenous Immunoglobulin (IVIG) Market Analysis
11.10.1. Market Size (US$ Mn) Forecast, by Indication
11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.10.1.2. Primary Humoral Immunodeficiency
11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.10.1.4. Guillain-Barre Syndrome
11.10.1.5. Myasthenia Gravis
11.10.1.6. Multifocal Motor Neuropathy (MMN)
11.10.1.7. Kawasaki Disease
11.10.1.8. Hypogammaglobulinemia
11.10.1.9. Chronic Lymphocytic Leukemia
11.10.1.10. Others
11.10.2. Market Size (US$ Mn) Forecast, by End-user
11.10.2.1. Hospitals
11.10.2.2. Clinics
11.10.2.3. Home Care Settings
11.11. Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.11.1. Market Size (US$ Mn) Forecast, by Indication
11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.11.1.2. Primary Humoral Immunodeficiency
11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.11.1.4. Guillain-Barre Syndrome
11.11.1.5. Myasthenia Gravis
11.11.1.6. Multifocal Motor Neuropathy (MMN)
11.11.1.7. Kawasaki Disease
11.11.1.8. Hypogammaglobulinemia
11.11.1.9. Chronic Lymphocytic Leukemia
11.11.1.10. Others
11.11.2. Market Size (US$ Mn) Forecast, by End-user
11.11.2.1. Hospitals
11.11.2.2. Clinics
11.11.2.3. Home Care Settings
12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Market Analysis, by Indication
12.3.1. Market Value Share Analysis, by Indication
12.3.2. Market Size (US$ Mn) Forecast, by Indication
12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.3.2.2. Primary Humoral Immunodeficiency
12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.3.2.4. Guillain-Barre Syndrome
12.3.2.5. Myasthenia Gravis
12.3.2.6. Multifocal Motor Neuropathy (MMN)
12.3.2.7. Kawasaki Disease
12.3.2.8. Hypogammaglobulinemia
12.3.2.9. Chronic Lymphocytic Leukemia
12.3.2.10. Others
12.4. Market Analysis, by End-user
12.4.1. Market Value Share Analysis, by End-user
12.4.2. Market Size (US$ Mn) Forecast, by End-user
12.4.2.1. Hospitals
12.4.2.2. Clinics
12.4.2.3. Home Care
12.5. Market Analysis, by Country/Sub-region
12.5.1. Market Value Share Analysis, by Country/Sub-region
12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.5.2.1. Brazil
12.5.2.2. Mexico
12.5.2.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By End-user
12.6.3. By Country/Sub-region
12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis
12.7.1. Market Size (US$ Mn) Forecast, by Indication
12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.7.1.2. Primary Humoral Immunodeficiency
12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.7.1.4. Guillain-Barre Syndrome
12.7.1.5. Myasthenia Gravis
12.7.1.6. Multifocal Motor Neuropathy (MMN)
12.7.1.7. Kawasaki Disease
12.7.1.8. Hypogammaglobulinemia
12.7.1.9. Chronic Lymphocytic Leukemia
12.7.1.10. Others
12.7.2. Market Size (US$ Mn) Forecast, by End-user
12.7.2.1. Hospitals
12.7.2.2. Clinics
12.7.2.3. Home Care Settings
12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis
12.8.1. Market Size (US$ Mn) Forecast, by Indication
12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.8.1.2. Primary Humoral Immunodeficiency
12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.8.1.4. Guillain-Barre Syndrome
12.8.1.5. Myasthenia Gravis
12.8.1.6. Multifocal Motor Neuropathy (MMN)
12.8.1.7. Kawasaki Disease
12.8.1.8. Hypogammaglobulinemia
12.8.1.9. Chronic Lymphocytic Leukemia
12.8.1.10. Others
12.8.2. Market Size (US$ Mn) Forecast, by End-user
12.8.2.1. Hospitals
12.8.2.2. Clinics
12.8.2.3. Home Care Settings
12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.9.1. Market Size (US$ Mn) Forecast, by Indication
12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.9.1.2. Primary Humoral Immunodeficiency
12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.9.1.4. Guillain-Barre Syndrome
12.9.1.5. Myasthenia Gravis
12.9.1.6. Multifocal Motor Neuropathy (MMN)
12.9.1.7. Kawasaki Disease
12.9.1.8. Hypogammaglobulinemia
12.9.1.9. Chronic Lymphocytic Leukemia
12.9.1.10. Others
12.9.2. Market Size (US$ Mn) Forecast, by End-user
12.9.2.1. Hospitals
12.9.2.2. Clinics
12.9.2.3. Home Care Settings
13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Market Analysis, by Indication
13.3.1. Market Value Share Analysis, by Indication
13.3.2. Market Size (US$ Mn) Forecast, by Indication
13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.3.2.2. Primary Humoral Immunodeficiency
13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.3.2.4. Guillain-Barre Syndrome
13.3.2.5. Myasthenia Gravis
13.3.2.6. Multifocal Motor Neuropathy (MMN)
13.3.2.7. Kawasaki Disease
13.3.2.8. Hypogammaglobulinemia
13.3.2.9. Chronic Lymphocytic Leukemia
13.3.2.10. Others
13.4. Market Analysis, by End-user
13.4.1. Market Value Share Analysis, by End-user
13.4.2. Market Size (US$ Mn) Forecast, by End-user
13.4.2.1. Hospitals
13.4.2.2. Clinics
13.4.2.3. Home Care
13.5. Market Analysis, by Country/Sub-region
13.5.1. Market Value Share Analysis, by Country/Sub-region
13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.5.2.1. GCC Countries
13.5.2.2. South Africa
13.5.2.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By End-user
13.6.3. By Country/Sub-region
13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis
13.7.1. Market Size (US$ Mn) Forecast, by Indication
13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.7.1.2. Primary Humoral Immunodeficiency
13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.7.1.4. Guillain-Barre Syndrome
13.7.1.5. Myasthenia Gravis
13.7.1.6. Multifocal Motor Neuropathy (MMN)
13.7.1.7. Kawasaki Disease
13.7.1.8. Hypogammaglobulinemia
13.7.1.9. Chronic Lymphocytic Leukemia
13.7.1.10. Others
13.7.2. Market Size (US$ Mn) Forecast, by End-user
13.7.2.1. Hospitals
13.7.2.2. Clinics
13.7.2.3. Home Care Settings
13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.8.1. Market Size (US$ Mn) Forecast, by Indication
13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.8.1.2. Primary Humoral Immunodeficiency
13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.8.1.4. Guillain-Barre Syndrome
13.8.1.5. Myasthenia Gravis
13.8.1.6. Multifocal Motor Neuropathy (MMN)
13.8.1.7. Kawasaki Disease
13.8.1.8. Hypogammaglobulinemia
13.8.1.9. Chronic Lymphocytic Leukemia
13.8.1.10. Others
13.8.2. Market Size (US$ Mn) Forecast, by End-user
13.8.2.1. Hospitals
13.8.2.2. Clinics
13.8.2.3. Home Care Settings
13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.9.1. Market Size (US$ Mn) Forecast, by Indication
13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.9.1.2. Primary Humoral Immunodeficiency
13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.9.1.4. Guillain-Barre Syndrome
13.9.1.5. Myasthenia Gravis
13.9.1.6. Multifocal Motor Neuropathy (MMN)
13.9.1.7. Kawasaki Disease
13.9.1.8. Hypogammaglobulinemia
13.9.1.9. Chronic Lymphocytic Leukemia
13.9.1.10. Others
13.9.2. Market Size (US$ Mn) Forecast, by End-user
13.9.2.1. Hospitals
13.9.2.2. Clinics
13.9.2.3. Home Care Settings
14. Company Profiles
14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2021)
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Baxalta Incorporated
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Biotest AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. China Biologic Products, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. CSL Behring LLC
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Grifols S.A.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Kedrion S.p.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. LFB Biomedicaments S.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Octapharma AG
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Sanquin Plasma Products B.V.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us